CD8A and neoplasm: Blockade of the complement receptor C5AR1 enables tumor-associated macrophages to be reprogrammed and reinvigorated CD8+ T-cell-mediated antitumor immunity, thereby synergizing with anti-PD-1 therapy for GC tumor eradication[47].